// App-Quantinova.ai

AB0774 : TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO

Researchers

Presenter

  • D. D. Gladman

Principal Investigators

  • L. C. Coates

  • J. Wu

  • L. Fallon

  • M. A. Hsu

  • A. G. Bushmakin

  • E. Bacci

  • J. C. Cappelleri

  • P. Helliwell

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Canada, Montreal, QC, Canada

  • Pfizer Inc., Collegeville, United States

  • Evidera, Seattle, United States of America

  • University of Leeds, Leeds, United Kingdom

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01877668]

  • NCT01882439]

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved